Recombinant IL-7/HGFβ efficiently induces transplantable murine hematopoietic stem cells

Laijun Lai,1,2,3 Mingfeng Zhang,3 and Irving Goldschneider1

1Department of Immunology and 2University of Connecticut Stem Cell Institute, School of Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA. 3Department of Allied Health Sciences, University of Connecticut, Storrs, Connecticut, USA.

Difficultly obtaining sufficient hematopoietic stem cells (HSCs) directly from the donor has limited the clinical use of HSC transplantation. Numerous attempts to stimulate the ex vivo growth of purified HSCs with cytokines and growth factors generally have induced only modest increases in HSC numbers while decreasing their in vivo reconstituting ability. We previously developed a recombinant single-chain form of a naturally occurring murine hybrid cytokine of IL-7 and the β chain of hepatocyte growth factor (rIL-7/HGFβ) that stimulates the in vitro proliferation and/or differentiation of common lymphoid progenitors, pre-pro-B cells, and hematopoietic progenitor cells (day 12 spleen colony-forming units) in cultures of mouse BM. Here we used the rIL-7/HGFβ in culture to induce large numbers of HSCs from multiple cell sources, including unseparated BM cells, purified HSCs, CD45− BM cells, and embryonic stem cells. In each instance, most of the HSCs were in the G0 phase of the cell cycle and exhibited reduced oxidative stress, decreased apoptosis, and increased CXCR4 expression. Furthermore, when injected i.v., these HSCs migrated to BM, self-replicated, provided radioprotection, and established long-term hematopoietic reconstitution. These properties were amplified by injection of rIL-7/HGFβ directly into the BM cavity but not by treatment with rIL-7, rHGF, and/or rHGFβ.

Introduction

An elusive goal in BM reconstitution therapy has been the establishment of conditions under which large numbers of transplantable hematopoietic stem cells (HSCs) can be selectively generated in vitro (1–4). Two major approaches using purified HSCs have been taken. In the first, gene transfer techniques featuring the overexpression of NOTCH-1, WNT, or HOXB4 were used to influence the survival and proliferation of HSCs in vitro (5–7). Although successful in several instances, this strategy has raised safety concerns that thus far have prohibited its clinical use.

In the second approach, a number of growth factors and soluble proteins were used to expand HSCs in vitro. Of the numerous cytokines that have been tested, none has thus far been able to stimulate the generation of sufficient functional HSCs for clinical application. This negative effect has been attributed to the decline or loss of long-term in vivo repopulating abilities (4, 5, 8) secondary to the entrance of HSCs into cell cycle (9–11). Therefore, only cytokines that maintain HSCs in G0 phase, such as SDF-1, TGF-β, FGF, and angiopoietin-1, have been found to preserve their engraftment ability (12–15).

Unfortunately, even these factors, whether used alone or in combination, were unable to stimulate sufficient HSC formation. Notably, the retroviral transduction of 5-FU-treated BM cells with the receptor for FGF-1 has shown promise (16). However, as FGF-1 has been shown to act indirectly by inducing other cells to stimulate HSCs, it is not known whether such an approach would be successful in cultures of purified HSCs.

Another approach to generating HSCs in vitro has used embryonic stem cells (ESCs), which are less prone than HSCs to replicative senescence and differentiation in vitro. However, the HSCs that have been produced by ESCs in stromal cell–dependent cultures lacked the ability to reconstitute the hematopoietic system efficiently when infused in vivo, possibly because they were not adult-type (definitive) HSCs (17).

We have demonstrated that a recombinant single-chain form of a naturally occurring, BM stromal cell–derived, hybrid cytokine consisting of murine IL-7 and the β chain of the hepatocyte growth factor (rIL-7/HGFβ) stimulates the expansion of day 12 spleen colony-forming units (CFU-S12), common lymphoid progenitors (CLPs), pre-pro-B cells, and thymocytes in vitro (18) and greatly enhances the thymopoiesis and naive T cell regeneration after BM transplantation in vivo (19). In this study, we show that rIL-7/HGFβ, but not its component cytokines, also stimulated the generation of large numbers of definitive HSCs in long-term cultures of adult BM cells. The results indicated that rIL-7/HGFβ maintains the hematopoietic reconstituting potential of these HSCs by inhibiting their proliferation, reducing oxidative stress and apoptosis, and increasing CXCR4 expression. Moreover, the fact that almost all of the culture-generated HSCs were in G0 phase raised the possibility that they had been generated by earlier precursors. This was confirmed by demonstrating that rIL-7/HGFβ induced the rapid generation of HSCs in short-term cultures of purified CD45−Lin−Sca-1+ BM cells, which have been reported to contain the most primitive cells in adult BM, including some that could serve (albeit inefficiently) as the precursors of HSCs in vivo (20–24). Furthermore, we demonstrated that rIL-7/HGFβ-responsive precursors of HSCs resided within the SSEA–IL-7Rα+c-Met+ subset of the CD45 Lin− BM cells.

In addition to stimulating the generation of HSCs from CD45− precursors, rIL-7/HGFβ was able to prevent proliferating HSCs from losing their in vivo repopulating abilities. This permitted...
large numbers of transplantable HSCs to be produced in rSCF- and rFlt3L-stimulated short-term cultures of unfractionated BM cells or purified HSCs. rIL-7/HGFβ was also able to induce murine ESCs to selectively form HSCs in OP-9 stromal cell cocultures, apparently through a CD45–Lin–SSEA+IL-7Rα+c-Met+ intermediate. In all of these systems, the culture-generated HSCs competitively established prolonged, multilineage hematopoietic cell chimerism in vivo. However, the ESC-derived HSCs required the injection of IL-7/HGFβ intrafemorally (i.f.) to establish hematopoietic chimerism, whereas this procedure helped to optimize, but was not essential for, the establishment of chimerism by the adult BM cell–derived HSCs. These in vitro and in vivo effects of the rIL-7/HGFβ fusion protein appeared to be unique, as they could not be replicated in whole or part by rIL-7, rHGF, and/or rHGFβ.

Results
rIL-7/HGFβ stimulates the in vitro production of CD45LinSca-1+c-Kit+ cells in long-term BM cell cultures. As we reported (18), mouse BM cells cultured in vitro for 3 to 4 weeks in the presence of rIL-7/HGFβ generated large numbers of CFU-S12, CLPs, pre-pro-B cells, and pro-B cells in vitro (data not shown). However, as shown in Figure 1, A–C, when the culture period was extended to 2 months, the number of CD19+ B-lineage cells decreased markedly and the numbers of CD45Lin (presumptive nonhematopoietic) cells and CD45LinSca-1+c-Kit+ (CD45-LSK) (presumptive hematopoietic stem and progenitor) cells increased markedly (5,000 and 14,000 cells/well, respectively), exceeding those in the original BM cell inoculum by 15- to 20-fold. More than 90% of the CD45Lin– cells incorporated BrdU within 45 minutes, and less than 2% were in G0 phase when stained with Ki-67 (Figure 1D). In contrast, less than 1% of the CD45-LSK cells (approximately 65% having the Flt3– phenotype of HSCs and 35% having the Flt3+ phenotype of multipotent progenitors [MPPs]) incorporated BrdU and were in G0 phase (Figure 1E). These results raised the possibility that most of the HSCs in these cultures had been generated by rapidly proliferating precursors, possibly among the CD45–Lin– cell population, and that the MPPs had differentiated from these HSCs, possibly without proliferation. Furthermore,
the effect of rIL-7/HGFβ on the generation of HSCs and MPPs in these cultures appeared to be unique, as PBS, rIL-7, and/or rHGF (or HGFβ; data not shown) supported the generation of CD45 Lin−, but not CD45LSK, cells.

Cells from rIL-7/HGFβ-stimulated BM cell cultures establish long-term hematopoietic chimerism in vivo. Competitive repopulating assays were conducted to determine whether the rIL-7/HGFβ-stimulated BM cells could reconstitute the hematopoietic system of lethally irradiated mice. In these experiments, 3 × 10⁴ cells from 2-month-old cultures of rIL-7/HGFβ, rIL-7−, and/or rHGF-stimulated (or HGF-stimulated) EGFP Tg BM cells were mixed with 2 × 10⁶ freshly harvested WT BM cells and injected i.v. into 10 Gy-irradiated WT recipients. Twelve weeks later, the blood was analyzed for donor-origin (GFP+) nucleated cells. As shown in Figure 2, only mice that received cells from the rIL-7/HGFβ-containing cultures displayed multilineage hematopoietic chimerism. In other experiments (Table 1), hematopoietic chimerism (14%–22% GFP+ cells) was observed in a variety of tissues (e.g., BM, blood [BL], spleen [SP], LN) as late as 21 weeks after adoptive transfer of 2-month-old cultures of rIL-7/HGFβ-stimulated BM cells; and the proportions of the major donor-origin leukocyte subsets generated were similar to those obtained when freshly harvested (noncultured) GFP+ BM cells were used as controls. Furthermore, the donor-origin BM cells in the experimental and control recipients demonstrated equivalent hematopoietic renewal potentials 12 weeks after i.v. injection into secondary irradiated recipients (Table 2).

To demonstrate more directly that the culture-generated HSCs were self-renewing, BM cells from the primary recipients were transferred at 14 weeks into irradiated secondary recipients, and the Lin− donor-origin BM cells were examined 4 weeks later. The results in Figure 3A show that approximately 15% of the total Lin+ cells in the BM of the secondary recipients were of donor origin. This was approximately twice that present in the BM that was transferred from the primary recipients. Furthermore, the subset distribution of the donor-origin Lin+ BM cells in the secondary recipients resembled that in the BM from the primary recipients, with the exception of a significant increase in the proportion of HSCs (Figure 3B).

It should be noted that no Ly5.2+GFP+ cells were observed in any of the chimeras (data not shown), indicating that fusion between donor-origin (Ly5.1+GFP+) and recipient (Ly5.2+GFP−) cells did not contribute to the observed hematopoietic reconstitution (25, 26). Importantly, no tumor formation was seen in any of the recipients observed for up to 8 months.

Table 1

<table>
<thead>
<tr>
<th>% of total donor-origin cells</th>
<th>BM</th>
<th>BL</th>
<th>SP</th>
</tr>
</thead>
<tbody>
<tr>
<td>T cells</td>
<td>2.1 ± 2.0</td>
<td>15.9 ± 13.4</td>
<td>17.0 ± 0.2</td>
</tr>
<tr>
<td></td>
<td>(0.7 ± 0.5)</td>
<td>(18.5 ± 9.0)</td>
<td>(22.9 ± 2.8)</td>
</tr>
<tr>
<td>B cells</td>
<td>26.2 ± 9.3</td>
<td>29.5 ± 5.9</td>
<td>25.2 ± 1.4</td>
</tr>
<tr>
<td></td>
<td>(26.7 ± 2.3)</td>
<td>(26.3 ± 9.1)</td>
<td>(42.8 ± 2.4)</td>
</tr>
<tr>
<td>Myeloid cells</td>
<td>14.6 ± 0.4</td>
<td>12.0 ± 3.5</td>
<td>6.3 ± 0.4</td>
</tr>
<tr>
<td></td>
<td>(9.4 ± 1.0)</td>
<td>(11.8 ± 1.9)</td>
<td>(7.6 ± 0.3)</td>
</tr>
<tr>
<td>Granulocytes</td>
<td>42.4 ± 2.6</td>
<td>52.1 ± 6.7</td>
<td>37.3 ± 4.5</td>
</tr>
<tr>
<td></td>
<td>(37.8 ± 6.7)</td>
<td>(50.5 ± 18.7)</td>
<td>(19.8 ± 3.5)</td>
</tr>
</tbody>
</table>

3 × 10⁴ cells from 2-month-old cultures of IL-7/HGFβ-stimulated BM (GFP+) were mixed with 2 × 10⁶ WT BM cells and injected i.v. into 10 Gy-irradiated WT recipients. For controls (indicated in parentheses), 2 × 10⁵ freshly harvested BM cells from GFP+ mice were mixed with 2 × 10⁶ WT BM cells. Twenty-one weeks later, the distribution of donor-origin (GFP+) Lin− cells in various tissues (red blood cells were lysed first) was determined by FACS analysis. Mean ± SD of 3 recipients; one representative experiment out of 3 is shown. *P < 0.05 between experimental and control values.

Table 2

<table>
<thead>
<tr>
<th>% of total donor-origin cells</th>
<th>BM</th>
<th>BL</th>
<th>SP</th>
</tr>
</thead>
<tbody>
<tr>
<td>T cells</td>
<td>5.3 ± 2.4</td>
<td>6.5 ± 7.8</td>
<td>13.4 ± 10.7</td>
</tr>
<tr>
<td></td>
<td>(4.5 ± 3.1)</td>
<td>(11.5 ± 2.4)</td>
<td>(16.4 ± 7.6)</td>
</tr>
<tr>
<td>B cells</td>
<td>16.4 ± 15.2</td>
<td>43.5 ± 16.9</td>
<td>59.4 ± 9.6</td>
</tr>
<tr>
<td></td>
<td>(13.4 ± 9.5)</td>
<td>(49.7 ± 11.1)</td>
<td>(58.5 ± 13.3)</td>
</tr>
<tr>
<td>Myeloid cells</td>
<td>6.0 ± 1.7</td>
<td>12.6 ± 2.9</td>
<td>7.8 ± 2.5</td>
</tr>
<tr>
<td></td>
<td>(5.9 ± 0.3)</td>
<td>(12.6 ± 3.3)</td>
<td>(7.9 ± 0.6)</td>
</tr>
<tr>
<td>Granulocytes</td>
<td>59.4 ± 16.6</td>
<td>58.5 ± 17.3</td>
<td>16.8 ± 11.6</td>
</tr>
<tr>
<td></td>
<td>(52.8 ± 12.0)</td>
<td>(49.3 ± 10.5)</td>
<td>(18.5 ± 3.9)</td>
</tr>
</tbody>
</table>

1 × 10⁴ BM cells, including controls (indicated in parentheses), obtained from primary recipients after 14 weeks, were mixed with 1.5 × 10⁶ WT BM cells and injected i.v. into 10 Gy-irradiated WT secondary recipients. Twelve weeks later, the distribution of donor-origin (GFP+) Lin− cells in various tissues was determined by FACS analysis. Mean ± SD of 3 recipients; one representative experiment out of 2 is shown.
Given our prior demonstration (19) that systemically injected rIL-7/HGFβ significantly enhanced thymocyteopoiesis after syngeneic BM transplantation, we determined whether i.f.-injected rIL-7/HGFβ would have a similar effect using culture-generated HSCs. As shown in Figure 4B, i.f. rIL-7/HGFβ induced a 2-fold increase in thymocyte chimerism over i.f. PBS (27% vs. 13%; P < 0.05). This suggested that one of the supportive effects of the systemic administration of rIL-7/HGFβ on thymopoiesis occurs at least partly in the BM (19).

Enhanced migration of hematopoietic stem and progenitor cells from the blood to the BM could be one of the mechanisms by which i.f. injection of rIL-7/HGFβ increases hematopoietic and thymopoietic chimerism. To test this, mice were injected i.f. with rIL-7/HGFβ and i.v. with cultured BM cells. As shown in Figure 5, i.f. injection of rIL-7/HGFβ significantly (P < 0.05) increased the number of rIL-7/HGFβ (but not rIL-7 or rHGF) culture-generated cells in the BM by 15- to 20-fold within 24 hours.

SCF and Flt3L accelerate the production of transplantable HSCs in short-term rIL-7/HGFβ-containing BM cultures. Early-acting cytokines, such as stem cell factor (SF) and Flt3 ligand (FL), are able to stimulate the proliferation of HSCs in vitro (30). However, these HSCs lose most of their in vivo hematopoietic repopulating capacity when they enter cell cycle. We therefore determined whether IL-7/HGFβ, which does not induce the proliferation of HSCs in vitro (Figure 1E), could preserve the long-term repopulating capacity of HSCs generated in the presence of SF and FL. In these experiments, 1 × 10^6 normal BM cells or 0.5 × 10^3 to 2 × 10^3 purified HSCs (Flt3−LSK cells) therefrom were cultured for 7 to 12 days with a mixture of SF and FL (SF/FL) in the presence or absence of rIL-7/HGFβ, rIL-7, and/or rHGF. Under these circumstances, all of the cultures contained elevated numbers of CD45+LSK cells (2 × 10^4 to 3 × 10^4), suggesting that, unlike long-term rIL-7/HGFβ-containing BM cell cultures, most of the HSCs in the short-term SF/FL-containing BM cell cultures were generated by the proliferation of preexisting HSCs. Yet, as shown in Figure 6, only the cells from the rIL-7/HGFβ-containing cultures were able to establish long-term (22–24 weeks) hematopoietic chimerism in adoptive recipients.

At least 4 differences between the rIL-7/HGFβ-containing cultures and those not containing rIL-7/HGFβ might help to explain these results. First, the LSK cells in the rIL-7/HGFβ-containing cultures expressed significantly lower levels of ROS than did their counterparts in non–rIL-7/HGFβ-containing cultures (Figure 7A). Second, a significantly lower proportion of the LSK cells in the
rIL-7/HGFβ-containing cultures incorporated BrdU (Figure 7B). Third, a significantly lower proportion of the LSK cells in the rIL-7/HGFβ-containing cultures were annexin V–positive (Figure 7C), including propidium iodide–positive and –negative subsets. Fourth, a significantly higher proportion of the LSK cells in the rIL-7/HGFβ-containing cultures expressed CXCR4 (Figure 7D). These effects were restricted to rIL-7/HGFβ and were not seen in cultures containing the individual factors rIL-7 and/or rHGFβ (data not shown). Hence, the addition of rIL-7/HGFβ to SF/FL-containing cultures appeared to maintain the hematopoietic reconstituting potential of these proliferating HSCs, at least in part, by protecting them against oxidative stress (possibly by enabling them to revert to the quiescent state; ref. 31), enhancing their survival, and increasing their ability to home to the BM (32).

rIL-7/HGFβ induces purified CD45 Lin Sca-1 BM cells and the CD45 Lin SSEA1IL-7Rαc-Met+ subset therein to generate HSCs in vitro. To test the hypothesis first suggested by the data in Figure 1 that most of the CD45 LSK cells in long-term rIL-7/HGFβ-containing BM cell cultures are generated by rIL-7/HGFβ precursors, we purified (>98%) CD45 Lin Sca-1 cells from normal BM and placed them in culture for 12 days in the presence of rIL-7/HGFβ, rIL-7, and/or rHGF (or PBS). As with the long-term BM cell cultures (Figure 1C), only the rIL-7/HGFβ-containing short-term cultures of purified CD45 Lin Sca-1 BM cells generated CD45 LSK cells. However, unlike the long-term BM cell cultures, CD45 LSK cells comprised approximately 30% (as opposed to 1%-2%) of the total cells in the short-term cultures of purified CD45 Lin Sca-1 BM cells (Figure 8A). Of these, approximately 75% were putative HSCs (Flk3+) and 25% were MPPs (Flt3+) (data not shown). Again, only the cells from the rIL-7/HGFβ-containing cultures competitively repopulated the hematopoietic system (Figure 8B) and provided radioprotection (data not shown) in vivo. In contrast, neither hematopoiesis nor radioprotection occurred when freshly purified CD45 Lin Sca-1 BM cells themselves were placed directly in vivo (Figure 8B and data not shown).

Consistent with published results (20), approximately 75% of the purified CD45 Lin Sca-1 BM cells were SSEA+ (data not shown), indicating that they were developmentally less mature than HSCs. In addition (and also unlike HSCs), approximately 30% of the SSEA+ cells expressed the IL-7Rα chain as well as c-Met, the receptor for HGF. Inasmuch as rIL-7/HGFβ acts selectively on dual receptor-expressing cells (ref. 18 and our unpublished observations), we hypothesized that, at a minimum, the SSEA+IL-7Rαc-Met+ subset of CD45 Lin BM cells contained the immediate precursors of the HSCs that are formed in these cultures. To test this, purified CD45 Lin SSEA+IL-7Rαc-Met+ BM cells were cultured for 12 days with rIL-7/HGFβ (or PBS). As shown in Figure 9A, these cultures generated HSCs, MPPs, megakaryocytic erythroid progenitors (MEPs), and CLPs in vitro. In addition, these cells competitively repopulated the hematopoietic system after i.v. injection into primary (Figure 9B) and secondary (Figure 9C) recipients. In contrast, CD45 Lin Sca-1 SSEA+ BM cells that failed to express IL-7Rα and c-Met did not generate HSCs, MEPs, MPPs, and CLPs in the presence of rIL-7/HGFβ (data not shown).

rIL-7/HGFβ enhances the generation of HSCs by ESCs in vitro. To further demonstrate that rIL-7/HGFβ can induce primitive precursors to generate HSCs in vitro, we cocultured undifferentiated murine ESCs (TC-1/EGFP) with OP9 cells for 12 days in the presence of equimolar amounts of rIL-7/HGFβ, rIL-7, and/or rHGF (or PBS). The cells from these cultures were then injected i.v. (2×105) into sublethally irradiated (6 Gy) 129SVEV Tac mice. As shown in Figures 10 and 11, only the cells from the rIL-7/HGFβ-containing ESC cocultures were able to reconstitute the hematopoietic system after i.v. injection. However, unlike the HSCs generated in cultures of purified CD45 Lin Sca-1 cells from adult BM (Figure 8), the ESC-derived HSCs required the i.f. injection of rIL-7/HGFβ to establish chimerism. Again, the i.f. injection of rIL-7/HGFβ (or rIL-7 and/or rHGF) to lethally irradiated 129SVEV Tac mice.
rHGF) was without effect when cells from the IL-7– and/or HGF-containing ESC cocultures were infused i.v. (data not shown). Nonetheless, as shown in Figure 12, the cells from all of the ESC cocultures (including the PBS controls) were able to establish low levels of BM chimerism when they themselves were injected i.f., and the levels of chimerism could be increased significantly by the concurrent i.f. injection of rIL-7/HGFβ. Even under these conditions, however, the i.f. injection of cells from the rIL-7/HGFβ-containing ESC cocultures established significantly higher levels of hematopoietic chimerism than did equal numbers of cells from the rIL-7– and/or HGF-containing cultures. However, even the donor-origin BM cells from the primary recipients of cells from the rIL-7/HGFβ-containing ESC cocultures were unable to establish hematopoietic chimerism when injected i.v. into secondary recipients without i.f. injection of rIL-7/HGFβ (data not shown).

These results suggest that the i.f. injection of rIL-7/HGFβ enabled the ESC-derived HSCs from the rIL-7/HGFβ-containing cocultures to migrate to and implant in the host BM but was unable to do so for their counterparts from the rIL-7– and/or HGF-containing (or PBS-containing) cocultures. However, when the need for cell migration was bypassed, the i.f. injection of rIL-7/HGFβ was also able to enhance the ability of the ESC-derived HSCs from the latter cocultures to establish hematopoietic chimerism. Hence, the ESC-derived HSCs from the rIL-7– and/or HGF-containing cocultures appeared to be less mature on average than were those from the rIL-7/HGFβ-containing cocultures; and these in turn appeared to be less mature than were the HSCs from the rIL-7/HGFβ-containing adult BM cell cultures, many of which could migrate to and implant in the BM in the absence of i.f.-injected rIL-7/HGFβ (Figure 2).

We then determined whether CD45−Lin−SSEA+IL-7Rα−c-Met+ HSC precursors were present in the ESC cultures. We found that 10- to 12-day-old murine ESC (TC-1/EGFP)/OP9 cell cocultures contained 2%–3% CD45−Lin−SSEA+IL-7Rα−c-Met+ cells, which when purified and stimulated in vitro with rIL-7/HGFβ, were able to reconstitute the hematopoietic system in vivo (Figure 13). These data suggest that, as in adult BM, CD45−Lin−SSEA+IL-7Rα−c-Met+ HSC precursors in ESC cultures can be induced by rIL-7/HGFβ to develop into HSCs.

**Discussion**

In their aggregate, the present data indicate that rIL-7/HGFβ can induce the generation of at least 3 distinct subsets of HSCs in vitro, each of which can establish long-term multilineage hematopoietic...
The signaling properties of rIL-7/HGFβ on many cell types (32, 38, 39). When combined with the unique signaling and to upregulate and/or activate adhesion molecules both HGF and IL-7 and with their abilities to enhance CXCR4 (35–37). It also is consistent with the antiapoptotic properties (32), to diminish oxidative stress-induced apoptosis (34), and to enhance the migration and adhesion of HSCs to BM niches (26–28). This is consistent with the known ability of HGF repairs the radiation-induced damage to the BM microenvironment. In addition, the level of chimerism could be significantly established long-term hematopoietic chimerism after i.v. injection. These HSC subsets can be distinguished operationally by their respective abilities to migrate to and/or implant in the BM of irradiated recipients in the presence or absence of i.f.-injected rIL-7/HGFβ. However, it is not known whether they represent different developmental stages of a single lineage or separate lineages that are produced at different stages of ontogeny (33).

The least mature subset of HSCs was generated by ESCs in OP-9 stromal cell cocultures that contained rIL-7 and/or rHGF (or PBS in lieu of cytokines). These HSCs did not migrate to the BM of irradiated recipients after i.v. injection, even when rIL-7/HGFβ had been injected i.f. However, they were able to establish low levels of hematopoietic chimerism when they were injected directly into the BM, and, under these circumstances, i.f.-injected rIL-7/HGFβ further enhanced their ability to do so. A subset of HSCs of intermediate maturity was generated by ESCs in OP-9 stromal cell cocultures that contained rIL-7/HGFβ. Although these cells did not migrate to the BM after i.v. injection, they could be induced to do so by the i.f. injection of rIL-7/HGFβ. Thus, even in the presence of rIL-7/HGFβ, ESCs did not generate definitive HSCs. The most mature subset of HSCs was generated by adult BM cells in cultures containing rIL-7/HGFβ. These adult BM-derived HSCs spontaneously migrated to the BM and established long-term hematopoietic chimerism after i.v. injection. In addition, the level of chimerism could be significantly enhanced by the i.f. injection of rIL-7/HGFβ.

In addition to enhancing the migration of HSCs to the BM, it is possible that locally injected rIL-7/HGFβ directly or indirectly repairs the radiation-induced damage to the BM microenvironment (26–28). This is consistent with the known ability of HGF to enhance the migration and adhesion of HSCs to BM niches (32), to diminish oxidative stress-induced apoptosis (34), and to interact synergistically with a variety of hematopoietic cytokines (35–37). It also is consistent with the antiapoptotic properties of both HGF and IL-7 and with their abilities to enhance CXCR4 signaling and to upregulate and/or activate adhesion molecules on many cell types (32, 38, 39). When combined with the unique signaling properties of rIL-7/HGFβ (see below), the results raise the additional possibility that rIL-7/HGFβ improves the BM microenvironment by increasing the local expression of molecules that regulate self-renewal, expansion, and/or fate determination of HSCs (40). One such defect may be related to the low levels of cytokine production in the irradiated BM, which adversely affect early B-lineage and T-lineage development and the mobilization of HSCs and MPPs (27–29, 41–43). Indeed, we have demonstrated here that i.f. injection of rIL-7/HGFβ significantly enhances thymocyte chimerism (Figure 4), and our recent demonstration that the systemic administration of rIL-7/HGFβ also rapidly restores thymocyteopoiesis after HSC transplantation strongly supports such a mechanism (19).

Although our initial observations were made in long-term rIL-7/HGFβ-containing BM cell cultures, it was possible to greatly accelerate the generation of transplantable HSCs in these cultures by administering rIL-7/HGFβ to lethally irradiated mice. The results of these studies support the hypothesis that rIL-7/HGFβ improves BM microenvironmental conditions and increases the number of hematopoietic progenitors that can engraft in the BM and contribute to long-term hematopoietic chimerism (27–29). Therefore, the administration of rIL-7/HGFβ to lethally irradiated mice provides an opportunity to study the effects of this cytokine on hematopoietic progenitors and the factors that regulate their engraftment, expansion, and differentiation in the BM.
(7 days vs. 2 months) when SF/FL was added. As confirmed in cultures initiated with purified HSCs, the SF/FL appeared to stimulate the proliferation of preexisting HSCs, whereas rIL-7/HGFβ helped to maintain the viability and function of these SF/FL-stimulated HSCs. The rIL-7/HGFβ acted at least in part by preventing oxidative stress and preserving (or inducing) the quiescent (G0) state of HSCs, possibly by enabling the proliferating HSCs in these cultures to reenter G0 phase and/or to upregulate genes implicated in HSC survival or migration (30, 31). However, as HSCs do not express the IL-7Rα chain, it is difficult to explain the superior protective ability of rIL-7/HGFβ, as compared with that of rHGF (or HGFβ) alone. One possibility is that rIL-7/HGFβ coordinately binds to and signals through c-Met and the γc chain. This is not implausible, as a functional hybrid receptor composed of the γc chain and the β chain of the GM-CSF receptor has been detected on human CD34+ hematopoietic cells (44). Another possibility is that the IL-7 component of rIL-7/HGFβ signals through other surface receptors, such as c-kit (45, 46). Whatever the mechanism, it is unlikely that rIL-7/HGFβ affects HSCs indirectly, as it is active in cultures of purified, SF/FL-stimulated HSCs.

In addition to preserving the hematopoietic reconstituting capacity of proliferating HSCs, it is possible that rIL-7/HGFβ further increases the size of the pool of transplantable HSCs in these short-term BM cell cultures by inducing the de novo formation of HSCs from CD45–Lin– precursors. This is supported by our demonstration that HSCs could be generated efficiently from all 3 germ layers, they originally were termed adult BM stem cells. However, this claim has been disputed, and it has been suggested instead that this primitive cell population has the appearance of pluripotency because it is composed of (or fuses with) a heterogenous mixture of tissue-committed stem cells (24, 25).

Regardless, some CD45 Lin–Sca-1+ BM cells, including similar somatic precursor cell populations in human BM and umbilical cord blood, have been reported to have the ability to generate multilineage HSCs in vivo or in vitro, albeit inefficiently (16, 20–23, 49–51). Importantly, we have demonstrated that purified CD45–Lin–SSEA+IL–7Rβc-Met+ cells from BM and ESC cultures can generate HSCs in the presence of rIL-7/HGFβ, suggesting these cells are HSC precursors. Based on our prior demonstration of the ability of rIL-7/HGFβ (as opposed to uncomplexed mixtures of IL-7 and HGFβ) to physically cross-link and aggregate the receptors for HGF and IL-7 on the cell surface (18, 19, 52), we predict that rIL-7/HGFβ can also cross-link the IL-7Rα and c-Met receptors on these HSC precursors, resulting in juxtacrine interactions and the appearance of phosphorylated downstream products that differ from those observed when each receptor signals independently, even if simultaneously (ref. 53 and our

Figure 12
The i.f. injection of rIL-7/HGFβ enhances the engraftment of i.f.-injected ESC-derived HSCs. 5 × 10^5 cells from rIL-7/HGFβ+, rIL-7 plus rHGF−, or PBS-containing ESC cocultures were mixed with rIL-7/HGFβ or PBS and injected i.f. into irradiated syngeneic recipients. Nine weeks later, the percentages of donor-origin (GFP+) cells in the BM of the recipients were determined. Mean ± SD of 4 to 5 mice per group. One representative experiment out of 2 is shown.
unpublished observations). In support of this hypothesis, we have observed the appearance of such distinct products in rIL-7/HGFβ cross-linked CLPs (unpublished observations).

It remains to be determined whether any of the short-term HSC-producing culture systems described here holds promise for clinical application when appropriately modified. At present, the cultures of adult BM cells appear to have advantages over those of ESCs in that they generate definitive HSCs, do not require stromal cell layers, do not require (but may benefit from) the injection of cytokine into the BM cavity, and do not run the risk of inducing teratomas. Although cultures using unseparated BM cells are the simplest to establish, cultures using purified HSCs or CD45–Lin–Sca-1+ or CD45 Lin SSEA-1+IL-7Rα+c-Met+ BM cells have the advantage of producing high proportions of CD45+LSK cells, thereby enabling HSCs to be easily purified prior to transplantation. In addition, untreated cultures of self-replicating CD45–Lin–Sca-1+ or CD45 Lin SSEA-1+IL-7Rα+c-Met+ BM cells have the potential to serve as reservoirs for the continuous or intermittent induction of HSCs by rIL-7/HGFβ and might also prove useful in HSC gene transfer therapy (54). Also, the production of HSCs in these cultures could be further amplified by the addition of SF/FL or other early-acting cytokines. Hence, by (a) stimulating the efficient in vitro production of transplantable HSCs from earlier precursors; (b) protecting proliferating HSCs against the loss of in vivo repopulating ability; (c) supporting the migration and engraftment of HSCs to/in the BM; and (d) enhancing thymocytopoiesis and naive T cell regeneration in irradiated recipients (unpublished observations), rIL-7/HGFβ has the potential to overcome several of the major obstacles to the widespread employment of HSC transplantation as a therapeutic modality.

### Methods

**Animals.** Ly 5 congenic C57BL/6NCR (B6) mice were obtained from the National Cancer Institute. EGFP transgenic mice that were backcrossed to the C57BL/6 genetic background were provided by Troy Randall (Trudeau Institute, Saranac Lake, New York, USA). The EGFP expression in these mice is controlled by the chicken actin promoter and CMV enhancer. Breeding pairs of IL-7Ra−/− mice (B6.129S7 mice) were purchased from The Jackson Laboratory.

**Antibodies.** FITC-, PE-, APC-, APC-Cy7-, or biotin-conjugated (or unconjugated) antibodies against mouse CD19, TER119, CD45, CD3, CD4, and CD8 (BioLegend); Ly 5.1, Ly 5.2, c-kit, Sca-1, Flt3, B220, Gr-1, CD11b, SSEA, CXCR4, and Ki-67 (BD Biosciences); and IL-7Rα chain (CD127) and c-Met (eBioscienes) were used. The BrdU Flow Kit was obtained from BD Biosciences, and anti-Biotin, APC, and PE MicroBeads were obtained from Miltenyi Biotec.

The expression of cell surface antigens (and GFP, annexin V, and propidium iodide) was determined by multicolor analysis on either a FACS-Calibur or LSR II flow cytometer (BD Biosciences). Lineage-negative (Lin−) cells were detected using a mixture of antibodies to CD3, Gr-1, CD11b, TER119, and B220. In adoptive transfer experiments, EGFP and/or Ly5.1 and Ly5.2 alleles were used to identify donor- and host-origin cells. Data were analyzed using FlowJo software (Tree Star Inc.). Background fluorescence for multicolor analysis was determined using mixtures of all of the conjugated antibodies minus the relevant antibody.

**FACS and immunomagnetic cell separation.** HSCs (CD45–Flt3–LSK cells) and CD45 Lin Sca-1+ BM cells were purified from normal mouse BM by combined immunomagnetic cell separation and FACS. The cells were stained with anti-CD45, developed with secondary antibody–conjugated Microbeads (Miltenyi Biotec), and applied to an LD column to separate the CD45+ and CD45− cell populations. The separated cells were stained with lineage and other markers, and the HSCs and CD45 Lin Sca-1+ or CD45 Lin SSEA-1+IL-7Rα+c-Met+ BM cells were further purified (>98%) by FACS sorting for use in cell culture or adoptive transfer experiments.

**Murine ESCs.** ESC line TC-1 (obtained from our Gene Targeting and Transgenic Facility) was derived from a 129SVEVTac blastocyst. The ESCs were maintained in an undifferentiated state by culture on embryonic fibroblasts (MEFs) and LIF and then adapted to serum-free and MEF-independent culture conditions by using ESGRO Complete serum-free clonal grade medium (Chemicon International Inc.). The ESCs were transfected by electroporation with pEGFP-N1 expression vector (Clontech), selected in ESGRO medium containing G418 in 96-well plates, and expanded to twenty-four 6-well plates after the cells grew to confluence. Although some of the clones lost expression of EGFP after several passages, we were able to select one clone that stably expressed EGFP for at least 24 passages following transfection. Like the WT ESCs, E6GF-ESCs expressed alkaline phosphatase, suggesting that they were in an undifferentiated state.

**BM cell culture.** BM was collected from the femurs and tibias of 4- to 6-week-old EGFP transgenic (C57BL/6 genetic background) or (129 X B6F1) mice and cultured (106 BM cells/well) in 6-well plates in RPMI-1640 plus 5% FBS and 25 ng/ml rHGF as described previously (18). rIL-7/HGFβ (30 ng/ml), rIL-7 (10 ng/ml), and/or rHGF (25 ng/ml) were added to the cultures as indicated (see Results). rIL-7 and HGF were purchased from R&D Systems. The single-chain rIL-7/HGFβ was expressed and purified as described previously (18). However, as the same results were obtained with rHGFβ as with rHGFβ, only the results using rHGFβ are shown. The cultures were refed with 50% fresh medium and cytokines twice weekly. For long-term cultures, total cells (nonadherent plus adherent) were harvested at 1 and 2 months and stained with fluorescent antibodies for phenotypic analysis. Short-term cultures (7–14 days) were set up in some experiments using whole BM, purified CD45 Lin Sca-1+, CD45 Lin SSEA-1+IL-7Rα+c-Met+ BM cells, or purified CD45−LSK Flt3− HSCs. In the ESC cultures, undifferentiated TC-1/EGFP ESCs were cocultured with OP9 cells, as described previously (55), and equimolar amounts of rIL-7/HGFβ (30 ng/ml), rIL-7 (10 mg/ml), and/or rHGFβ (20 mg/ml) were added to the cultures initially and whenever the...
medium was changed. In the whole BM cell cultures, rSCF (50 ng/ml) plus rFlt3L (50 ng/ml) was added to the medium alone or in combination with the above cytokines.

**Competitive in vivo transplantation assays.** Cultured BM cells were mixed in indicated numbers (see Results) with 2 × 10^5 freshly harvested host-type BM cells and injected via tail vein into irradiated (10 Gy) recipients. Some of the mice were also injected i.f. with rIL-7/HGFβ (500 ng once per month), as described previously (56). Blood samples and tissues were collected at the indicated times (see Results), and donor-origin cells were quantified and analyzed for the expression of lineage markers. To assess radioprotection, cultured BM cells were injected i.v. into lethally irradiated (10 Gy) mice without competitor BM cells. A radioprotection end point of 6 weeks was used.

**BrdU incorporation.** 10 μl of 1 mM BrdU solution (BD Biosciences) was added per ml of cultured BM cells. The treated cells were incubated at 37°C for 45 minutes and stained with conjugated antibodies for cell-surface markers. After fixation and treatment with DNase, the permeabilized cells were stained with APC-labeled anti-BrdU antibody and analyzed by flow immunocytometry.

**Analysis of intracellular ROS.** Cytokine-cultured BM cells were loaded with 5 μM 2′,7′-dichlorofluorescein diacetate (DCF-DA) (Sigma-Aldrich) and incubated on a shaker at 37°C for 30 minutes. The cells were then stained with antibodies for LSK and analyzed by flow cytometry. The peak excitation wavelength for oxidized DCF was 488 nm, and that for emission was 525 nm.

**Statistics.** P values were based on 2-tailed Student’s t test. A confidence level above 95% (P < 0.05) was determined as significant.

**Study approval.** All mice were housed under specific pathogen-free conditions in the Center for Laboratory Animal Care, University of Connecticut Health Center and University of Connecticut, and were used according to protocols approved by the Institutional Animal Care and Use Committee of University of Connecticut and University of Connecticut Health Center.

**Acknowledgments**

This study was supported in part by NIH grant AI32752 and a grant from the Connecticut Stem Cell Research Program (10SCB12).

Received for publication April 26, 2012, and accepted in revised form July 26, 2012.

**Address correspondence to:** Irving Goldschneider, Department of Immunology, School of Medicine, University of Connecticut Health Center, 263 Farmington Ave., Farmington, Connecticut 06030, USA. Phone: 860.679.2936; Email: igoldsch@neuron.uchc.edu. Or to: Laijun Lai, Department of Allied Health Sciences, University of Connecticut, 1390 Storrs Road, Storrs, Connecticut 06269, USA. Phone: 860.679.6073; Fax: 860.486.6073; Email: lalaijun.lai@uconn.edu.


